Sertraline and desmethylsertraline in human breast milk and nursing infants.

Sertraline and desmethylsertraline in human breast milk and nursing infants. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Sertraline and desmethylsertraline in human breast milk and nursing infants. Abstract Text:

OBJECTIVE: The purpose of this study was to determine the concentrations of sertraline and desmethylsertraline in both human breast milk and infant serum. METHOD: Breast milk samples from 12 women were collected at specific time intervals after oral doses of sertraline (25-200 mg once daily). For 11 mother-infant pairs, maternal serum levels 24 hours after a dose and their infants' serum levels 2-4 hours after nursing were ascertained by high-performance liquid chromatography. RESULTS: Sertraline and desmethylsertraline were present in all breast milk samples, with a gradient from "fore" milk to "hind" milk. The highest concentrations of sertraline were observed in hind milk 7-10 hours after maternal dose. Increasing the maternal dose of sertraline resulted in increased breast milk concentrations of both sertraline and desmethylsertraline. Detectable concentrations of sertraline were found in three nursing infants and desmethylsertraline in six. No adverse effects of exposure were observed in any infant. CONCLUSIONS: Sertraline and desmethylsertraline were present in the breast milk of nursing women treated with sertraline. Concentrations were affected by aliquot of milk sampled, time after maternal dose, and maternal daily dose. The infants' serum concentrations detected were below the detection limit of most commercial laboratories. The presence of desmethylsertraline in six infants' samples underscores the importance of metabolite monitoring in determining infant exposure. Estimates of daily infant exposure can be determined after analysis of sertraline and desmethylsertraline concentrations from one full breast at maternal serum steady state. Future studies of breast milk and infant serum samples should address these issues.

Sertraline and desmethylsertraline in human breast milk and nursing infants. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Sertraline and desmethylsertraline in human breast milk and nursing infants. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The American journal of psychiatry

VOLUME: 154

Page Numbers: 1255-60

Journal Abbreviation:

ISSN: 0002-953X

DAY: 6

MONTH: Sep

YEAR: 1997

Sertraline and desmethylsertraline in human breast milk and nursing infants. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370512

Sertraline and desmethylsertraline in human breast milk and nursing infants. Keywords Mesh Terms:

KEYWORDS: Sertraline

MESH TERMS: pharmacokinetics

Chemical & Substance for Abstract: Sertraline and desmethylsertraline in human breast milk and nursing infants. Information

Substance Name: desmethylsertraline

Registry Number: 87857-41-8

Grant and Affiliation Information for Sertraline and desmethylsertraline in human breast milk and nursing infants.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.

Country: UNITED STATES

AGENCY: United States NIMH

GRANT: MH-51761

ACRONYM: MH

MEDLINETA: Am J Psychiatry

REFSOURCE: Am J Psychiatry. 1998 Nov;155(11):1643-4

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Sertraline and desmethylsertraline in human breast milk and nursing infants Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.